Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
10.44
-0.31 (-2.88%)
Apr 29, 2026, 10:22 AM EDT - Market open
Immunic Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
92
Market Cap
136.21M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Innate Pharma | 10.57M |
| Alpha Cognition | 10.22M |
| Equillium | 4.39M |
| Kazia Therapeutics | 1.27M |
| Cardiff Oncology | 593.00K |
| Connect Biopharma Holdings | 64.00K |
IMUX News
- 1 day ago - Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D. - PRNewsWire
- 6 days ago - Immunic, Inc. Announces 1-for-10 Reverse Stock Split - PRNewsWire
- 11 days ago - Immunic's Next-Gen Oral Multiple Sclerosis Drug Poised To Capture Share, Analyst Says - Benzinga
- 20 days ago - Immunic to Participate in Scientific and Medical Conferences in April - PRNewsWire
- 4 weeks ago - Immunic Regains Compliance with Nasdaq Minimum Bid Price Requirement - PRNewsWire
- 4 weeks ago - Immunic Strengthens Its Board of Directors with the Appointment of Seasoned Biopharmaceutical Executive Jon Congleton - PRNewsWire
- 5 weeks ago - Immunic Transcript: Stifel 2026 Virtual CNS Forum - Transcripts
- 6 weeks ago - Immunic Transcript: Leerink Global Healthcare Conference 2026 - Transcripts